CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst

CRISPR Therapeutics AG CRSP reported new topline study results on Wednesday to establish risk factors for atherosclerotic heart disease.The company disclosed data regarding the first 10 patients across its Phase 1 first-in-human dose escalation trial, targeting ANGPTL3 in four patient groups with elevated low-density lipoprotein (LDL), triglyceride (TG), or both.The data comes from the first 10 patients across the first four cohorts (lean body weight-based doses of DL1 [0.1 mg/kg], DL2[0.3 mg/kg], DL3 [0.6 ...